Last reviewed · How we verify
Tauvid (FLORTAUCIPIR F 18)
Tauvid (generic name: FLORTAUCIPIR F 18) is a Small molecule drug developed by Avid Radiopharms Inc. It is currently FDA-approved (first approved 2020) for Positron emission tomography.
Tauvid binds to tau protein in the brain, allowing for visualization of tau pathology through PET imaging.
Tauvid (Flortaucipir F 18) is a positron emission tomography (PET) imaging agent developed by AVID RADIOPHARMS INC. It targets the microtubule-associated protein tau, which is associated with neurodegenerative diseases. Tauvid is used for diagnostic purposes to visualize tau pathology in the brain. It was FDA-approved in 2020 for this indication. As a patented product, it is not yet available as a generic version.
At a glance
| Generic name | FLORTAUCIPIR F 18 |
|---|---|
| Sponsor | Avid Radiopharms Inc |
| Target | Microtubule-associated protein tau |
| Modality | Small molecule |
| Therapeutic area | Neuroscience |
| Phase | FDA-approved |
| First approval | 2020 |
Mechanism of action
Flortaucipir 18 binds to aggregated tau protein. In the brains of patients with AD, tau aggregates combine to form NFTs, one of two components required for the neuropathological diagnosis of AD. In vitro, flortaucipir 18 binds to paired helical filament (PHF) tau purified from brain homogenates of donors with AD. The dissociation constant (Kd) of flortaucipir 18 binding to PHFs is 0.57 nM. In vivo, flortaucipir 18 is differentially retained in neocortical areas that contain aggregated tau. In vitro, tritiated flortaucipir has been reported to bind with low nanomolar affinity to monoamine oxidase-A and monoamine oxidase-B, which could contribute to off target binding.
Approved indications
- Positron emission tomography
Common side effects
- Headache
- Injection site pain
- Increased blood pressure
Key clinical trials
- Alzheimer's Disease Neuroimaging Initiative 4
- A First-In-Human Study of LY3954068 in Participants With Early Symptomatic Alzheimer's Disease (PHASE1)
- Sex-Specific Effects of Endocrine Disruption on Aging and Alzheimer's Disease (PHASE4)
- 18F-AV-1451 High Resolution Autopsy Study (PHASE1)
- Neuroimaging in Healthy Aging and Senile Dementia (HASD_IND)
- F 18 T807 Tau PET Imaging of Alzheimer's Disease
- Imaging of Brain Structural/Functional Connectivity and Amyloid and Tau Lesions in APOE4 Carriers.
- A Study of LY3303560 in Participants With Mild Cognitive Impairment or Alzheimer's Disease (PHASE1)
Patents
| Patent | Expiry | Type |
|---|---|---|
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| FDA label | Mechanism, indications, dosing, boxed warnings, drug interactions |
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
| FDA Orange Book | Patents + exclusivity |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Tauvid CI brief — competitive landscape report
- Tauvid updates RSS · CI watch RSS
- Avid Radiopharms Inc portfolio CI
Frequently asked questions about Tauvid
What is Tauvid?
How does Tauvid work?
What is Tauvid used for?
Who makes Tauvid?
What is the generic name of Tauvid?
When was Tauvid approved?
What development phase is Tauvid in?
What are the side effects of Tauvid?
What does Tauvid target?
Related
- Target: All drugs targeting Microtubule-associated protein tau
- Manufacturer: Avid Radiopharms Inc — full pipeline
- Therapeutic area: All drugs in Neuroscience
- Indication: Drugs for Positron emission tomography
- Compare: Tauvid vs similar drugs
- Pricing: Tauvid cost, discount & access